The role for interleukin-12 therapy of cutaneous T cell lymphoma

Annals of the New York Academy of Sciences

Volumn 941, Issue , 2001, Pages 177-184

  Rook, Alain H ^a   Zaki, Mohamed H ^a   Wysocka, Maria ^a   Wood, Gary S ^a   Duvic, Madeleine ^a   Showe, Louise C ^a   Foss, Francine ^a   Shapiro, Michael ^a   Kuzel, Timothy M ^a   Olsen, Elise A ^a   Vonderheid, Eric C ^a   Laliberte, Robert ^a   Sherman, Matthew L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Interferon ; Interleukin 2; Recombinant human interleukin 12

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12;

ADULT; ANTINEOPLASTIC ACTIVITY; ANXIETY; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INTERFERON PRODUCTION; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SKIN LYMPHOMA; T CELL LYMPHOMA;

EID: 0034803597     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03721.x     Document Type: Conference Paper

References (24)

1. Mycosis fungoides and Sézary syndrome
2. Detection of clonal T-cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoides/Sézary syndrome
3. Mycosis fungoides and the Sézary syndrome: Pathology, staging and treatment
4. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma
5. 382 IL-2 fusion toxin in cutaneous T-cell lymphoma
6. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma
7. Immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sézary T-cells
8. Depressed lymphokine activated killer cell activity in mycosis fungoides
9. Aberrant cytokine production by Sézary syndrome patients. Cytokine secretion pattern resembles murine Th2 cells
10. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain)
11. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10
12. Interleukin-12: A cytokine at the interface of inflammation and immunity
13. Induction of IFN gamma production by NK cell stimulatory factor (NKSF): Characterization of the responder cells and synergy with other inducers
14. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
15. Interleukin-12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors
16. Interleukin 12 reverses cytokine and immune abnormalities in Sézary syndrome
17. + tumor-infiltrating lymphocytes influence survival of patients with mycosis fungoides
18. Detection of clonal T-cell receptor γ gene rearrangements in early mycosis fungoides/Sézary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE)
19. Mycosis fungoides skin lesions contain CD8 positive tumor infiltrating lymphocytes expressing an activated MHC restricted cytotoxic T-lymphocyte phenotype
20. Large cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: Molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor
21. Depressed interleukin-12 mediated signal transduction in T-cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta2 mRNA expression
22. Interleukin-12 signaling in T helper type (Th1)1 cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat) 3 and Stat 4
23. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
24. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4